Evidence map›Paper›PMID 27585525›Full record

ArticleStem cell research & therapy2016

Comparative study of allogenic and xenogeneic mesenchymal stem cells on cisplatin-induced acute kidney injury in Sprague-Dawley rats.

Rehab H Ashour, Mohamed-Ahdy Saad, Mohamed-Ahmed Sobh, Fatma Al-Husseiny, Mohamed Abouelkheir, Amal Awad, Doaa Elghannam, Hassan Abdel-Ghaffar, Mohamed Sobh

Open access · goldAbstract readComparative Study
In one paragraph

Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Bioactivity ofPlants (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease.Frontiers in cell and developmental biology · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Locoregional delivery of stem cell-based therapies.Science translational medicine · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Rehab H AshourClinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt. zohoor26203@yahoo.com.
Mohamed-Ahdy SaadClinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed-Ahmed SobhZoology Unit-Urology and Nephrology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Fatma Al-HusseinyPathology Department, Mansoura University, Mansoura, Egypt.
Mohamed AbouelkheirClinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Amal AwadMedical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Doaa ElghannamClinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Hassan Abdel-GhaffarClinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed SobhMedical Experimental Research Center (MERC), Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe paracrine and regenerative activities of mesenchymal stem cells (MSCs) may vary with different stem cell sources. The aim of the present study is to compare the effects of MSCs from different sources on acute kidney injury (AKI) induced by cisplatin and their influence on renal regeneration.

methodsA single intraperitoneal injection of cisplatin (5 mg/kg) was used to induce AKI in 120 Sprague-Dawley rats. Rats were treated with either rat bone marrow stem cells (rBMSCs), human adipose tissue-derived stem cells (hADSCs), or human amniotic fluid-derived stem cells (hAFSCs). 5 × 10(6) MSCs of different sources were administered through rat tail vein in a single dose, 24 hours after cisplatin injection. Within each group, rats were sacrificed at the 4th, 7th, 11th, and 30th day after cisplatin injection. Serum creatinine, BUN, and renal tissue oxidative stress parameters were measured. Renal tissue was scored histopathologically for evidence of injury, regeneration, and chronicity. Immunohistochemistry was also done using Ki67 for renal proliferative activity evaluation.

resultsMSCs of the three sources were able to ameliorate cisplatin-induced renal function deterioration and tissue damage. The rat BMSCs-treated group had the lowest serum creatinine by day 30 (0.52 ± 0.06) compared to hADSCs and hAFSCs. All MSC-treated groups had nearly equal antioxidant activity as indicated by the decreased renal tissue malondialdehyde (MDA) and increased reduced glutathione (GSH) level and superoxide dismutase (SOD) activity at different time intervals. Additionally, all MSCs improved injury and regenerative scores. Rat BMSCs had the highest count and earliest proliferative activity in the renal cortex by day 7 as identified by Ki67; while, hAFSCs seem to have the greatest improvement in the regenerative and proliferative activities with a higher count of renal cortex Ki67-positive cells at day 11 and with the least necrotic lesions.

conclusionsRat BMSCs, hADSCs, and hAFSCs, in early single IV dose, had a renoprotective effect against cisplatin-induced AKI, and were able to reduce oxidative stress markers. Rat BMSCs had the earliest proliferative activity by day 7; however, hAFSCs seemed to have the greatest improvement in the regenerative activities. Human ADSCs were the least effective in the terms of proliferative and regenerative activities.

Indexed as

Acute Kidney InjuryAnimalsCell ProliferationCells, CulturedCisplatinCreatinineFemaleGlutathioneHumansKidneyMalondialdehydeMesenchymal Stem CellsMesenchymal Stem Cell TransplantationOxidative StressRatsRats, Sprague-DawleyCisplatinCreatinineGlutathioneMalondialdehydeSuperoxide DismutaseAdipose-derivedAmniotic fluid-derivedCisplatin nephrotoxicityMesenchymal stem cells

Identifiers

PMID27585525
PMCPMC5009659
OpenAlexW2509821316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.